|
Sign In to gain access to subscriptions and/or personal tools.
|
Assessment of Human Cancer Risk: Challenges for Alternative Approaches
Gilbert S. Omenn
The University of Michigan, Ann Arbor, Michigan
The ILSI/HESI Workshopon Alternatives to Carcinogenicity Testing aims to develop and apply new methods for assessment of potential carcinogenic risk to humans from various chemicals. The Workshoprepresents a major cooperative scientific effort. The long-term goals should be to greatly enhance the effi ciency and reliability of such testing and to supplant, not just supplement, lifetime rodent bioassays. There are now well-established frameworks for risk assessment and risk management, putting risks into public health context and engaging stakeholders. The Lave-Omenn value-of-information model provides a useful way to assess the social costs and benefits of different strategies for testing large numbers of chemicals.
Key Words: Cancer risk assessment • risk management • cost-effectiveness analysis • public health context • value-of-information model • social costs.
References
- Ashby J., Tennant RW (1994). Prediction of rodent carcinogenicity of 44 chemicals: Results. Mutagenesis 9: 7—15.[Abstract/Free Full Text]
- Calkins DR, Dixon RL, Gerber CR, Zarin D., Omenn GS (1980). Identifi cation, characterization, and control of potential human carcinogens: A framework for federal decision-making. J Natl Cancer Inst 61: 169—175.
- deSerres Fj, Ashby J (eds) (1981). Evaluation of Short-Term Tests for Carcinogens: Report of the International Collaborative Program, Elsevier, New York.
- EPA (1996a). Food Quality Protection Act (FQPA): Offi ce of Pesticide Programs, Washington DC.
- EPA (1996b). Proposed Guidelines for Carcinogen Risk Assessment. EPA/ 600/P-92/003C). Offi ce of Research and Development, Washington DC.
- EPA (1998). Chemical Hazard Availability Study. EPA Offi ce of Pollution Prevention and Toxics, Washington DC.
- FaustmanEM, Omenn GS (2001). Risk assessment. In: CasarettandDoull's Toxicology, 6th ed, Klaassen CD (ed). McGraw-Hill, New York, pp. 83—104.
- GoldLS, Manley NB, SloneTH, RohrbachL. (1999). Supplementto the CarcinogenicPotency Database (CPDB): Results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. Environ Health Perspect 107, Suppl 4: 527—600.[Web of Science][Medline]
[Order article via Infotrieve]
- Gold LS, Slone TH, Ames BN ( 1998). What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metabolism Reviews 30: 359—404.[Web of Science][Medline]
[Order article via Infotrieve]
- Goldberg L (ed) (1973). Carcinogenesis Testing on Chemicals, CRC Press, Boca Raton, Florida.
- Hill AB (1965). The environment and disease: Association or causation? Proc Roy Soc Med 58: 295—300.[Web of Science][Medline]
[Order article via Infotrieve]
- International Conference on Harmonization, Expert Working Group on Safety (1996). Draft guideline on testing for carcinogenicity of pharmaceuticals. Fed Reg 61: 43298—43300.
- Lave LB, Ennever FK, Rosenkranz HS, Omenn GS (1988). Information value of the rodent bioassay. Nature 336: 631—633.[CrossRef][Medline]
[Order article via Infotrieve]
- Lave LB, Omenn GS (1986). Cost-effectiveness of short-term tests for carcinogenicity. Nature 324: 29—34.[CrossRef][Medline]
[Order article via Infotrieve]
- McClain RM (1994). Mechanistic considerations in the regulation and classifi cation of chemical carcinogens. In: Nutritional Toxicolocy, Kotsonis F, Mackey M, Hijele J (eds). Raven, New York, pp 278—304.
- National Research Council ( 1994). Science and Judgment in Risk Assessment. National Academy Press, Washington, DC.
- Omenn GS (2000). The post-genomic era: A crucial role for the public health sciences. Environ Health Perspect 108: 160—161.[CrossRef]
- Omenn GS, Faustman EM (2001). Risk assessment and risk management. In: Oxford Textbook of Public Health, 4th ed, Detels R, McEwen J, Baeglehole R, Tanaka H (eds). In press.
- Omenn GS, Lave LB ( 1988). Scientifi c and cost-effectiveness criteria in selecting batteries of short-term tests. Mutation Res 205: 41—49.[CrossRef][Medline]
[Order article via Infotrieve]
- Omenn GS, Stuebbe S., Lave LB ( 1995). Predictions of rodent carcinogenicity testing results: Interpretation in light of the Lave-Omenn Value-of-Information Model. Molecular Carcinogenesis 14: 37—45.[CrossRef]
- Pereira MA, Stoner GD (1985). Comparison of rat liver foci assay and strain A mouse lung tumor assay to detect carcinogens: A review. Fund Appl Toxicol 5: 688—699.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Presidential/Congressional Commission on Risk Assessment and Risk Management (1997a,b). A Framework for Environmental Health Risk Management (Vol 1); Risk Assessment and Risk Management in Regulatory Decision-Making (Vol 2). Government Printing Offi ce, Washington, DC.
- Roe D., Pease W., Florini K., Silbergeld E. (1997). Toxic Ignorance. Environmental Defense Fund, Washington, DC.
- Robinson D. (1998). International Life Sciences Institute's role in the evaluation of alternative methodology for the assessment of carcinogenic risk. Toxicol Pathol 26: 474—475.[Free Full Text]
- Tennant RW, Spalding JW, Stasiewicz S., Ashby J. (1990). Prediction of the outcome of rodent carcinogenicity bioassays currently being conducted on 44 chemicals by the U.S. National Toxicology Program. Mutagenesis 5: 3—14.
Toxicologic Pathology, Vol. 29, No. 1 suppl,
5-12 (2001)
DOI: 10.1080/019262301753178429
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
